ReviewFrontiers in cell and developmental biology2023

Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations.

Konstantin H Dragnev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.